Ultima Labs
3rd Party Tested & Certified Research Grade Peptides
CJC 1295 DAC 5MG
For research purposes only. Not for human consumption.
CJC-1295 DAC 5mg — Extended-Release GHRH Research Analogue
CJC-1295 DAC 5mg is a synthetic analogue of growth hormone-releasing hormone (GHRH) modified with Drug Affinity Complex (DAC) technology enabling albumin binding. This modification substantially extends the peptide half-life compared to native GHRH, producing a prolonged and sustained growth hormone-releasing profile that has made it a frequently utilised compound in long-duration research protocols.
Research Applications
Research employing CJC-1295 DAC has investigated sustained stimulation of the somatotropic axis, examining prolonged growth hormone pulse patterns, extended IGF-1 responses, and downstream metabolic effects of persistent GH elevation. Scientists have studied this GHRH analogue in combination with ghrelin receptor agonists such as Ipamorelin, investigating synergistic GH responses and the physiological implications of sustained versus pulsatile GH release.
Formulation & Purity
Supplied as a high-purity white lyophilised powder, this product exceeds >99% purity as verified by HPLC analysis. Its freeze-dried formulation ensures long-term structural stability, maintaining peptide integrity throughout storage and transport. Researchers may reconstitute the compound using bacteriostatic water or a sterile diluent suited to their experimental protocol.
Intended Use
CJC-1295 DAC 5mg is intended exclusively for in vitro and non-clinical scientific research. It is not approved for human or animal therapeutic, diagnostic, or medicinal use. All handling and experimentation must be conducted by trained professionals within appropriate controlled laboratory environments.
